Cargando…
Public research funding and pharmaceutical prices: do Americans pay twice for drugs?
In the debate over prescription drug pricing, some pharmaceutical industry critics claim that U.S. taxpayers pay twice for costly therapies, because publicly supported research is a major contributor to drug discovery and American taxpayers are inadequately rewarded for their research investment due...
Autores principales: | Conti, Rena M., David, Frank S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000 Research Limited
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7642989/ https://www.ncbi.nlm.nih.gov/pubmed/33204410 http://dx.doi.org/10.12688/f1000research.24934.1 |
Ejemplares similares
-
Paying for On-Patent Pharmaceuticals: Limit Prices and the Emerging Role of a Pay for Outcomes Approach
por: Fuller, Richard L., et al.
Publicado: (2016) -
Access Denied? The Unintended Consequences of Pending Drug Pricing Rules
por: Kaplan, Alan, et al.
Publicado: (2022) -
Science Matters It pays to fund research
Publicado: (2009) -
The mission to ensure continued funding for excellent basic research
por: Lamond, Angus I., et al.
Publicado: (2023) -
The Price She Pays
por: Poole, W. C.
Publicado: (1913)